Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells (Q49851572)

22 February 2018

title

Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells (English)

1 reference

22 February 2018

author name string

Varun Sasidharan Nair

series ordinal

1 reference

22 February 2018

Eyad Elkord

series ordinal

1 reference

22 February 2018

publication date

17 November 2017

1 reference

22 February 2018

Immunology & Cell Biology

published in

1 reference

22 February 2018

volume

1 reference

22 February 2018

issue

1 reference

22 February 2018

page(s)

21-33

1 reference

22 February 2018

Regulatory T cells: mechanisms of differentiation and function

cites work

1 reference

Regulatory T cells in autoimmmunity*.

21 January 2018

1 reference

Thymus and Reproduction: Sex-Linked Dysgenesia of the Gonad after Neonatal Thymectomy in Mice

21 January 2018

1 reference

Study on cellular events in postthymectomy autoimmune oophoritis in mice. I. Requirement of Lyt-1 effector cells for oocytes damage after adoptive transfer

21 January 2018

1 reference

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

21 January 2018

1 reference

Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse

21 January 2018

1 reference

JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome

21 January 2018

1 reference

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

Control of regulatory T cell development by the transcription factor Foxp3

21 January 2018

1 reference

Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?

21 January 2018

1 reference

X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy

21 January 2018

1 reference

Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice

21 January 2018

1 reference

Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting

21 January 2018

1 reference

Regulatory T cells in cancer immunotherapy

21 January 2018

1 reference

Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer

21 January 2018

1 reference

Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma

21 January 2018

1 reference

Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions

21 January 2018

1 reference

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer

21 January 2018

1 reference

Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma

21 January 2018

1 reference

Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer

21 January 2018

1 reference

Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers

21 January 2018

1 reference

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

21 January 2018

1 reference

Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model

21 January 2018

1 reference

Role of LAG-3 in regulatory T cells.

21 January 2018

1 reference

TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression

21 January 2018

1 reference

Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses

21 January 2018

1 reference

How regulatory T cells work

21 January 2018

1 reference

Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells

21 January 2018

1 reference

Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells

21 January 2018

1 reference

Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege

21 January 2018

1 reference

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

21 January 2018

1 reference

Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta

21 January 2018

1 reference

A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.

21 January 2018

1 reference

CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.

21 January 2018

1 reference

Targeting regulatory T cells in cancer

21 January 2018

1 reference

Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets

21 January 2018

1 reference

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation

21 January 2018

1 reference

Roles of LAG3 and EGR2 in regulatory T cells.

21 January 2018

1 reference

Intratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer

21 January 2018

1 reference

CTLA-4 can function as a negative regulator of T cell activation

21 January 2018

1 reference

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

21 January 2018

1 reference

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

21 January 2018

1 reference

Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis

21 January 2018

1 reference

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses

21 January 2018

1 reference

Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation

21 January 2018

1 reference

Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood

21 January 2018

1 reference

CTLA-4 control over Foxp3+ regulatory T cell function

21 January 2018

1 reference

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

21 January 2018

1 reference

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

21 January 2018

1 reference

CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis

21 January 2018

1 reference

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer

21 January 2018

1 reference

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer

21 January 2018

1 reference

Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.

21 January 2018

1 reference

Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells

21 January 2018

1 reference

The PD-1-PD-L pathway in immunological tolerance

21 January 2018

1 reference

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

21 January 2018

1 reference

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

21 January 2018

1 reference

PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.

21 January 2018

1 reference

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

PD-1 regulates extrathymic regulatory T-cell differentiation

21 January 2018

1 reference

PD-1 is not required for natural or peripherally induced regulatory T cells: Severe autoimmunity despite normal production of regulatory T cells

21 January 2018

1 reference

PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells

21 January 2018

1 reference

Programmed Death Ligand 1 Plays a Neuroprotective Role in Experimental Autoimmune Neuritis by Controlling Peripheral Nervous System Inflammation of Rats.

21 January 2018

1 reference

PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient

21 January 2018

1 reference

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood.

21 January 2018

1 reference

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells

21 January 2018

1 reference

PD-1 marks dysfunctional regulatory T cells in malignant gliomas

21 January 2018

1 reference

In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates

21 January 2018

1 reference

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

21 January 2018

1 reference

CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteins

21 January 2018

1 reference

LAG-3, a novel lymphocyte activation gene closely related to CD4

21 January 2018

1 reference

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems

21 January 2018

1 reference

Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells

21 January 2018

1 reference

LAG-3 regulates plasmacytoid dendritic cell homeostasis

21 January 2018

1 reference

LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites

21 January 2018

1 reference

MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.

21 January 2018

1 reference

T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding

21 January 2018

1 reference

Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens

21 January 2018

1 reference

Galectin-3: an open-ended story

21 January 2018

1 reference

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

21 January 2018

1 reference

Highly prevalent colorectal cancer-infiltrating LAP⁺ Foxp3⁻ T cells exhibit more potent immunosuppressive activity than Foxp3⁺ regulatory T cells

21 January 2018

1 reference

Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease

21 January 2018

1 reference

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

21 January 2018

1 reference

Tim-3 expression defines regulatory T cells in human tumors

21 January 2018

1 reference

TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

21 January 2018

1 reference

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

21 January 2018

1 reference

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance

21 January 2018

1 reference

A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC

21 January 2018

1 reference

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function

21 January 2018

1 reference

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

21 January 2018

1 reference

Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112)

21 January 2018

1 reference

Cutting edge: TIGIT has T cell-intrinsic inhibitory functions

21 January 2018

1 reference

TIGIT predominantly regulates the immune response via regulatory T cells.

21 January 2018

1 reference

Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226.

21 January 2018

1 reference

Immune checkpoint inhibitors side effects and management

21 January 2018

1 reference

Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/IMCB.1003

1 reference

22 February 2018

1 reference

22 February 2018